Mirum Pharmaceuticals, Inc. MIRM Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$798.84M-3,319% | -$23.36M+43.6% | -$41.42M+29.3% | -$58.56M+24.3% | -$77.34M+12.1% | ||
| $25.07M+3.4% | $24.24M+0.1% | $24.23M0.0% | $24.22M+0.8% | $24.02M+1.6% | ||
| $91.82M+28.6% | $71.42M+8.8% | $65.65M+10.5% | $59.43M+12.6% | $52.8M+9.0% | ||
| $1.76M+1.2% | $1.74M+1.2% | $1.72M+1.1% | $1.7M+1.2% | $1.68M+1.1% | ||
| $44.11M-8.2% | $48.06M+20.4% | $39.91M-11.0% | $44.87M+8.8% | $41.23M+261% | ||
| $7.7M-8.9% | $8.45M+32.4% | $6.38M+4.2% | $6.12M+25.6% | $4.87M+53.9% | ||
| —— | —— | —— | —— | —— | ||
| $1.32M-5.6% | $1.4M+0.9% | $1.39M-7.0% | $1.49M+4.3% | $1.43M+80.1% | ||
| -$2.07M-9.2% | -$1.9M-18.7% | -$1.6M-42.2% | -$1.12M-21.9% | -$921K-17.8% | ||
| -$170.98M-406% | $55.83M— | —— | —— | —— | ||
| $1.58M+65.3% | $954K+155% | $374K+1.6% | $368K-64.0% | $1.02M+2.8% | ||
| $98.7M+1.3% | $97.43M0.0% | $97.41M+5.7% | $92.15M-24.8% | $122.55M+37.7% | ||
| $90.88M+22.1% | $74.43M+1.3% | $73.46M+17.7% | $62.39M+67.1% | $37.33M+87.6% | ||
| $10M— | $0— | $0-100% | $10M-50.0% | $20M0.0% | ||
| -$20.4M+18.3% | -$24.96M0.0% | -$24.96M+38.8% | -$40.77M+61.9% | -$106.89M-17.8% | ||
| $3.77M— | $0-100% | $31.14M+107% | $15.05M+137% | $6.36M— | ||
| $303.86M+657% | $40.14M+10.0% | $36.48M+50.4% | $24.25M+6.1% | $22.85M+29.1% | ||
| —— | —— | $2.25M+13.1% | $1.99M+661% | -$355K+72.6% | ||
| $114.39M+52.0% | $75.24M+27.3% | $59.11M+1,308% | -$4.89M+94.6% | -$90.6M-42.9% | ||
| $2.22M+2.7% | $2.16M-9.5% | $2.38M+3.1% | $2.31M+125% | $1.03M+2.3% | ||
| $1.76M+1.2% | $1.74M+1.2% | $1.72M+1.1% | $1.7M+1.2% | $1.68M+1.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $2.06M+392% | $419K+102% | $207K-83.9% | ||
| $95.61M+90.8% | $50.1M-10.5% | $56M+26.1% | $44.41M+8.9% | $40.77M+1.1% | ||
| —— | —— | —— | —— | —— | ||
| -$2.07M-9.2% | -$1.9M-18.7% | -$1.6M-42.2% | -$1.12M-21.9% | -$921K-17.8% | ||
| $10.37M+83.1% | $5.66M+40.6% | $4.03M+46.4% | $2.75M+71.9% | $1.6M+6.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.73M-80.8% | ||
| $1.89M+9.2% | $1.73M+5.4% | $1.64M+2.9% | $1.6M+5.8% | $1.51M+11.3% | ||
| $1.32M-5.6% | $1.4M+0.9% | $1.39M-7.0% | $1.49M+4.3% | $1.43M+80.1% | ||
| $10M— | $0— | $0-100% | $10M-50.0% | $20M0.0% | ||
| $90.88M+22.1% | $74.43M+1.3% | $73.46M+17.7% | $62.39M+67.1% | $37.33M+87.6% | ||
| —— | —— | —— | —— | —— | ||
| $43.91M+9.4% | $40.14M+10.0% | $36.48M+50.4% | $24.25M+6.1% | $22.85M+29.1% | ||
| $18K-25.0% | $24K+41.2% | $17K+88.9% | $9K+50.0% | $6K— | ||
| —— | —— | $2.25M+13.1% | $1.99M+661% | -$355K+72.6% | ||
| -$2.07M-9.2% | -$1.9M-18.7% | -$1.6M-42.2% | -$1.12M-21.9% | -$921K-17.8% | ||
| $2.82M+8.8% | $2.59M+12.8% | $2.3M+26.3% | $1.82M+16.0% | $1.57M+23.1% | ||
| —— | —— | —— | —— | —— | ||
| $6.92M+183% | $2.44M— | —— | —— | —— | ||
| $649K-5.7% | $688K-9.0% | $756K+3.6% | $730K-34.8% | $1.12M-0.2% | ||
| —— | —— | —— | —— | —— | ||
| $2.22M+2.7% | $2.16M-9.5% | $2.38M+3.1% | $2.31M+125% | $1.03M+2.3% | ||
| -$172.55M-414% | $54.87M— | —— | —— | —— | ||
| -$172.55M-414% | $54.87M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Mirum Pharmaceuticals, Inc. generate?
- Mirum Pharmaceuticals, Inc. (MIRM) generated -$171.0M in operating cash flow over the trailing twelve months.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- After $1.6M of capital expenditures, Mirum Pharmaceuticals, Inc.'s free cash flow was -$172.6M over the trailing twelve months, down 45270.7% year over year.
- Where does Mirum Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Mirum Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
